Key Insights

Highlights

Success Rate

75% trial completion

Published Results

65 trials with published results (26%)

Research Maturity

85 completed trials (34% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

11.2%

28 terminated out of 249 trials

Success Rate

75.2%

-11.3% vs benchmark

Late-Stage Pipeline

7%

18 trials in Phase 3/4

Results Transparency

76%

65 of 85 completed with results

Key Signals

65 with results75% success28 terminated

Data Visualizations

Phase Distribution

214Total
Not Applicable (62)
Early P 1 (7)
P 1 (32)
P 2 (95)
P 3 (15)
P 4 (3)

Trial Status

Completed85
Recruiting57
Active Not Recruiting45
Terminated28
Unknown18
Withdrawn8

Trial Success Rate

75.2%

Benchmark: 86.5%

Based on 85 completed trials

Clinical Trials (249)

Showing 20 of 20 trials
NCT05109208Not ApplicableRecruitingPrimary

The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction

NCT07635238Phase 2Recruiting

A Study of Lower Dose Radiation Therapy for People With Prostate Cancer

NCT03899987Phase 2Active Not RecruitingPrimary

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

NCT04190446Phase 2Active Not Recruiting

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

NCT05665738Not ApplicableRecruitingPrimary

Two-fraction HDR Monotherapy for Localized Prostate Cancer

NCT06499870Phase 2RecruitingPrimary

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT05616650Phase 2Recruiting

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT03821246Phase 2RecruitingPrimary

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

NCT06235151Phase 3Recruiting

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

NCT05751434Phase 2Active Not Recruiting

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

NCT04519879Phase 2SuspendedPrimary

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

NCT07552168Phase 2RecruitingPrimary

INSPIRE: INnovative SABR for Prostate Cancer All IREland

NCT04530552Phase 2Active Not Recruiting

Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland

NCT04126070Phase 2Active Not Recruiting

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT03570827Phase 2CompletedPrimary

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

NCT05496959Phase 2Active Not Recruiting

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

NCT03503643Completed

Hemi-Gland Cryoablation for Prostate Cancer at UCLA

NCT07468903Not ApplicableRecruitingPrimary

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

NCT05931419Recruiting

High-Risk prostatE Cancer radiatiOn Versus surgERy

NCT04037254Phase 1CompletedPrimary

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Scroll to load more

Research Network

Activity Timeline